JP2022542543A5 - - Google Patents
Info
- Publication number
- JP2022542543A5 JP2022542543A5 JP2022502899A JP2022502899A JP2022542543A5 JP 2022542543 A5 JP2022542543 A5 JP 2022542543A5 JP 2022502899 A JP2022502899 A JP 2022502899A JP 2022502899 A JP2022502899 A JP 2022502899A JP 2022542543 A5 JP2022542543 A5 JP 2022542543A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- acid sequence
- sequence
- cdr2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015341A JP2025069305A (ja) | 2019-07-17 | 2025-01-31 | 抗ｄｌｌ３キメラ抗原受容体及びその使用 |
| JP2025156914A JP2026001061A (ja) | 2019-07-17 | 2025-09-22 | 抗ｄｌｌ３キメラ抗原受容体及びその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019096360 | 2019-07-17 | ||
| CNPCT/CN2019/096360 | 2019-07-17 | ||
| CN2020090587 | 2020-05-15 | ||
| CNPCT/CN2020/090587 | 2020-05-15 | ||
| PCT/CN2020/102717 WO2021008610A1 (en) | 2019-07-17 | 2020-07-17 | Anti-dll3 chimeric antigen receptors and uses thereof |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015341A Division JP2025069305A (ja) | 2019-07-17 | 2025-01-31 | 抗ｄｌｌ３キメラ抗原受容体及びその使用 |
| JP2025156914A Division JP2026001061A (ja) | 2019-07-17 | 2025-09-22 | 抗ｄｌｌ３キメラ抗原受容体及びその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542543A JP2022542543A (ja) | 2022-10-05 |
| JP2022542543A5 true JP2022542543A5 (https=) | 2023-07-21 |
| JP7748933B2 JP7748933B2 (ja) | 2025-10-03 |
Family
ID=74210175
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022502899A Active JP7748933B2 (ja) | 2019-07-17 | 2020-07-17 | 抗ｄｌｌ３キメラ抗原受容体及びその使用 |
| JP2025015341A Pending JP2025069305A (ja) | 2019-07-17 | 2025-01-31 | 抗ｄｌｌ３キメラ抗原受容体及びその使用 |
| JP2025156914A Pending JP2026001061A (ja) | 2019-07-17 | 2025-09-22 | 抗ｄｌｌ３キメラ抗原受容体及びその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015341A Pending JP2025069305A (ja) | 2019-07-17 | 2025-01-31 | 抗ｄｌｌ３キメラ抗原受容体及びその使用 |
| JP2025156914A Pending JP2026001061A (ja) | 2019-07-17 | 2025-09-22 | 抗ｄｌｌ３キメラ抗原受容体及びその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12421292B2 (https=) |
| EP (2) | EP4527466A3 (https=) |
| JP (3) | JP7748933B2 (https=) |
| KR (1) | KR20220035367A (https=) |
| CN (4) | CN114072427B (https=) |
| AU (1) | AU2020314509A1 (https=) |
| CA (1) | CA3146019A1 (https=) |
| TW (2) | TW202535924A (https=) |
| WO (1) | WO2021008610A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115298223A (zh) | 2020-03-12 | 2022-11-04 | 南京传奇生物科技有限公司 | 磷脂酰肌醇蛋白聚糖-2结合部分、嵌合抗原受体及其用途 |
| EP4313081A4 (en) * | 2021-04-02 | 2025-04-09 | Nanjing Legend Biotech Co., Ltd. | MANIPULATED IMMUNE CELLS AND THEIR USES |
| AU2022339815A1 (en) * | 2021-09-02 | 2024-03-14 | Memorial Hospital For Cancer And Allied Diseases | Antigen recognizing receptors targeting dll3 and uses thereof |
| AU2023297866A1 (en) * | 2022-06-28 | 2024-12-12 | Resolution Therapeutics Limited | Switch receptors and modified immune cells |
| JP2025525496A (ja) * | 2022-07-08 | 2025-08-05 | イマジナブ・インコーポレーテッド | Ｄｌｌ３抗原結合構築物 |
| WO2024044779A2 (en) * | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
| CN115820698B (zh) * | 2022-11-22 | 2025-01-21 | 浙江康佰裕生物科技有限公司 | 含有嵌合抗原受体和嵌合转换开关受体编码基因的融合基因及其应用 |
| CN116004547B (zh) * | 2023-03-06 | 2025-04-25 | 浙江康佰裕生物科技有限公司 | 一种辐照car-t细胞及其制备方法与应用 |
| CN121152872A (zh) * | 2023-05-10 | 2025-12-16 | 南京传奇生物科技有限公司 | 嵌合抗原受体及其使用方法 |
| AU2024347905A1 (en) * | 2023-09-26 | 2026-04-02 | Legend Biotech Ireland Limited | Dll3 binding moieties and uses thereof |
| WO2025201493A1 (zh) * | 2024-03-29 | 2025-10-02 | 诺纳生物（苏州）有限公司 | Dll3结合分子及其用途 |
| WO2025212519A1 (en) * | 2024-04-01 | 2025-10-09 | Moonlight Bio, Inc. | Dll3 binding proteins and uses thereof |
| WO2025240849A1 (en) * | 2024-05-16 | 2025-11-20 | The Brigham And Women's Hospital, Inc. | Trem2 chimeric antigen receptors and uses thereof |
| WO2026008059A1 (en) * | 2024-07-04 | 2026-01-08 | Nanjing Legend Biotech Co., Ltd. | Anti-dll3 constructs and uses thereof |
| CN119708238B (zh) * | 2025-02-27 | 2025-07-04 | 昕传生物科技(北京)有限公司 | 靶向dll3的抗体、嵌合抗原受体及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| DK1034298T3 (da) | 1997-12-05 | 2012-01-30 | Scripps Research Inst | Humanisering af murint antistof |
| MA41613A (fr) | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
| CN105153315B (zh) | 2015-10-09 | 2019-04-02 | 重庆精准生物技术有限公司 | 免疫抑制受体联合肿瘤抗原嵌合受体及其应用 |
| CN109863242A (zh) | 2016-08-30 | 2019-06-07 | 纪念斯隆-凯特林癌症中心 | 用于治疗病毒感染和其它感染的免疫细胞组合物和使用方法 |
| CN108276493B (zh) * | 2016-12-30 | 2023-11-14 | 南京传奇生物科技有限公司 | 一种嵌合抗原受体及其应用 |
| CN110536700A (zh) | 2017-04-19 | 2019-12-03 | 南加利福尼亚大学 | 用于治疗癌症的组合物和方法 |
| WO2019067805A1 (en) * | 2017-09-27 | 2019-04-04 | University Of Southern California | NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY |
| EP3774921A4 (en) | 2018-04-03 | 2022-01-05 | Dragonfly Therapeutics, Inc. | ANTIBODY VARIABLE DOMAINS AGAINST DLL3 AND USE OF IT |
| JP7479290B2 (ja) * | 2018-04-10 | 2024-05-08 | アムジエン・インコーポレーテツド | Ｄｌｌ３に対するキメラ受容体及びその使用方法 |
-
2020
- 2020-07-17 EP EP25154055.5A patent/EP4527466A3/en active Pending
- 2020-07-17 CA CA3146019A patent/CA3146019A1/en active Pending
- 2020-07-17 TW TW114114222A patent/TW202535924A/zh unknown
- 2020-07-17 CN CN202080047990.8A patent/CN114072427B/zh active Active
- 2020-07-17 CN CN202311129421.XA patent/CN117106099A/zh active Pending
- 2020-07-17 AU AU2020314509A patent/AU2020314509A1/en active Pending
- 2020-07-17 JP JP2022502899A patent/JP7748933B2/ja active Active
- 2020-07-17 KR KR1020227000346A patent/KR20220035367A/ko active Pending
- 2020-07-17 WO PCT/CN2020/102717 patent/WO2021008610A1/en not_active Ceased
- 2020-07-17 TW TW109124309A patent/TWI883026B/zh active
- 2020-07-17 US US17/618,642 patent/US12421292B2/en active Active
- 2020-07-17 CN CN202410399887.XA patent/CN118496374A/zh active Pending
- 2020-07-17 EP EP20840073.9A patent/EP3999550A4/en active Pending
- 2020-07-17 CN CN202410399472.2A patent/CN118420777A/zh active Pending
-
2025
- 2025-01-31 JP JP2025015341A patent/JP2025069305A/ja active Pending
- 2025-08-22 US US19/308,077 patent/US20260078166A1/en active Pending
- 2025-09-22 JP JP2025156914A patent/JP2026001061A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022542543A5 (https=) | ||
| US20260078166A1 (en) | Anti-dll3 chimeric antigen receptors and uses thereof | |
| JP6669722B2 (ja) | Ｃｄ３結合ドメイン | |
| JP2025065142A5 (https=) | ||
| JP2022518925A5 (https=) | ||
| JP2024125370A (ja) | クローディン１８．２結合部分およびその利用 | |
| JP2017527275A5 (https=) | ||
| JP2015527070A5 (https=) | ||
| JP2018538277A5 (https=) | ||
| US11945878B2 (en) | Switch molecule and switchable chimeric antigen receptor | |
| CN111378044B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| JP2024508672A (ja) | 新規抗ｃｄ２４抗体 | |
| JP2024504162A5 (https=) | ||
| JP2023554467A5 (https=) | ||
| JP7730432B2 (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｃｌｄｎ４－抗ｃｄ１３７二重特異性抗体の使用 | |
| JP2024539079A5 (https=) | ||
| JP2023549441A5 (https=) | ||
| JP2023535485A (ja) | 抗ｃｄ２２シングルドメイン抗体および治療用コンストラクト | |
| JP2025087939A (ja) | がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用 | |
| HK40110781A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| HK40110214A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| HK40098926A (zh) | 一种抗dll3嵌合抗原受体及其用途 | |
| HK40065826A (zh) | 抗dll3嵌合抗原受体及其用途 | |
| HK40065826B (zh) | 抗dll3嵌合抗原受体及其用途 |